

24  
Claims

What is claimed is:

1. A biphasic injectable composition for tissue volume replacement
  - a solid polymer phase; and
  - a carrier substrate phase.
2. The composition of Claim 1, wherein the solid polymer phase is made from micronized expanded polytetrafluoroethelene (“e-PTFE”) particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly ε-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.
3. The composition of Claim 1, wherein the solid polymer phase is made from at least two of micronized expanded polytetrafluoroethelene (“e-PTFE”) particles, polydioxanone, long chain aliphatic polymers Nylon 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly ε-caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or polyhydroxyvalerate.
4. The composition of Claim 1, wherein the carrier substrate phase is selected from polyvinylpyrrolidone (“PVP”), silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.
5. The composition of Claim 1 wherein the solid polymer phase comprises micronized expanded polytetrafluoroethelene (“e-PTFE”) particles.

6. The composition of Claim 5, wherein the e-PTFE particles range in size from approximately 65 to 1000 micrometers.

5 7. The composition of Claim 1, wherein the carrier substrate phase is PVP.

8. The composition of Claim 7, wherein the PVP comprises a K value from approximately less than 12 to 100.

10 9. The composition of Claim 7, wherein the PVP comprises a K value from approximately less than 12 to 50.

15 10. The composition of Claim 7, wherein the PVP comprises a K value from approximately less than 12 to 20.

11. The composition of Claim 7, wherein the PVP comprises a K value of 17.

20 12. The composition of Claim 1, wherein the solid polymer phase comprises e-PTFE; and  
the carrier substrate phase comprises PVP.

25 13. The composition of Claim 12 wherein the e-PTFE and the PVP are combined at a ratio of approximately 3:2 PVP to e-PTFE by weight.

30 14. The composition of Claim 1, wherein the carrier substrate phase comprises micronized polydioxanone particles ranging in size from approximately 65 to 1000 micrometers

35 15. A method for tissue augmentation comprising:  
injecting a biphasic injectable composition comprising:  
a solid polymer phase; and  
a carrier substrate phase.

16. The method of Claim 15, wherein the solid polymer phase is made from micronized expanded polytetrafluoroethylene ("e-PTFE") particles, polydioxanone, long chain aliphatic polymers Nylon 5 6, long chain aliphatic polymers Nylon 6,6, polypropylene, copolymer made from 90% glycolide and 10% L-lactide, silk, poly  $\epsilon$ -caprolactone, polylactide, polyglycolide, poly lactide-co-glycolide, polyhydroxyvalerate, biocompatible micronized polyethylene, bioactive glass particulate, synthetic bone graft particulate, or 10 polyhydroxyvalerate.

17. The method of Claim 15, wherein the carrier substrate phase is selected from polyvinylpyrrolidone ("PVP"), silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, 15 water or autologous plasma.

18. The method of Claim 15, wherein injecting comprises:

20 inserting a delivery apparatus containing the biphasic injectable composition into the injection site.

19. The method of Claim 15, wherein the injecting comprises subcutaneous, intradermal, intramuscular, periurethral injection or injecting the vocal cords.

25